Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE versus TENATHAN.
Head-to-head clinical analysis: NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE versus TENATHAN.
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE vs TENATHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Diphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms and inducing sedation via central H1 blockade.
TENATHAN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, leading to increased serotonin levels in the synaptic cleft.
One tablet (naproxen sodium 220 mg / diphenhydramine hydrochloride 25 mg) orally every 8 hours as needed, not to exceed 2 tablets in 24 hours.
1 tablet (40 mg) orally once daily, increased to 80 mg once daily if needed after 4 weeks.
None Documented
None Documented
Naproxen: 12-17 hours (mean ~14 hours); clinically, allows twice-daily dosing for sustained anti-inflammatory effect. Diphenhydramine: 4-10 hours (mean ~7 hours); shorter half-life supports sedative effect for sleep induction.
Terminal elimination half-life is 4-6 hours; in severe renal impairment (CrCl <30 mL/min) may extend to 8-12 hours, requiring dose adjustment.
Naproxen: renal excretion of naproxen and its metabolites (95% as unchanged drug and conjugated metabolites, primarily 6-O-desmethylnaproxen). Diphenhydramine: renal excretion of unchanged drug and metabolites (primarily as diphenylmethoxyacetic acid); approximately 50-60% eliminated in urine as unchanged drug and metabolites, with a small fraction in feces.
Primarily renal excretion as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for <10%.
Category D/X
Category C
NSAID
NSAID